RemAb Therapeutics
A biopharmaceutical company developing injectable polymer conjugates designed to selectively remove harmful circulating antibodies, with potential applications in infections, allergies, autoimmune disease, and gene therapy.
About RemAb Therapeutics
Biopharmaceutical research
RemAb Therapeutics is a biopharmaceutical company based at the Autonomous University of Barcelona campus in Bellaterra, Cerdanyola del Vallès. Its work focuses on identifying, characterizing, and selectively removing specific antibodies using its proprietary HART (Harmful Antibody Removal Technology) platform.
HART technology
The company is developing and optimizing injectable synthetic polymer conjugates designed to bind to harmful antibodies circulating in the blood. The resulting immune complex is metabolized and excreted quickly. The company says this may provide patients with an immediate and lasting clinical benefit. Its described process has four stages: harmful antibodies are present; the polymer conjugate is administered; an antibody-conjugate complex forms; and the immune complex is cleared.
Potential applications
- Bacterial infections
- Allergy
- Blood group incompatibility
- Autoimmune disease
- Gene therapy, including modulation of the immune response to viral vectors
The company also identifies potential applications in infectious diseases, transplantation, and transfusion medicine.
Contact
Address: Avinguda Can Domènech, no number, Research Module B, UAB Campus, Bellaterra, 08193 Cerdanyola del Vallès, Barcelona, Spain. Email: info@remabtx.com.
Harmful antibody removal technology